$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

아스트라제네카 코로나19 백신(ChAdOx1 nCoV-19/AZD1222)을 접종한 환자에서 한방 치료의 안전성 : 사례군 연구
Safety of Korean Medicine Treatment in Patients Vaccinated with the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19/AZD1222): A Case Series 원문보기

대한한방내과학회지 = The journal of internal Korean medicine, v.42 no.4, 2021년, pp.590 - 604  

강성우 (경희대학교 대학원 임상한의학과 폐계내과학교실) ,  홍성은 (경희대학교 대학원 임상한의학과 폐계내과학교실) ,  박지원 (경희대학교 대학원 임상한의학과 폐계내과학교실) ,  권승원 (경희대학교 한의과대학 순환신경내과학교실) ,  윤상협 (경희대학교 한의과대학 비계내과학교실) ,  김관일 (경희대학교 대학원 임상한의학과 폐계내과학교실) ,  이범준 (경희대학교 대학원 임상한의학과 폐계내과학교실) ,  정희재 (경희대학교 대학원 임상한의학과 폐계내과학교실)

Abstract ▼ AI-Helper 아이콘AI-Helper

Objectives: The purpose of this study is to examine the safety of Korean medicine treatment in patients vaccinated with the AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19/AZD1222). Methods: We investigated patients at Kyung Hee University Korean Medicine Hospital who were vaccinated with the AstraZen...

주제어

#adverse event   #AZD1222   #COVID-19 vaccine   #Korean traditional medicine   #safety  

표/그림 (3)

참고문헌 (22)

  1. Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann Intern Med 2021;174(5) :687-90. 

    상세보기 crossref

  2. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria TM , SII COVISHIELD TM ). Accessed August 6, 2021, https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1 

  3. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021;397(10269):99-111. 

    상세보기 crossref

  4. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 2021;397(10277):881-91. 

    상세보기 crossref

  5. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 2020;396(10249): 467-78. 

    상세보기 crossref

  6. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine. Accessed August 6, 2021, https://www.who.int/news/item/07-04-2021-interim-statement-of-the-covid-19-subcommittee-of-the-who-global-advisory-committee-on-vaccine-safety 

  7. Peltier E. Denmark says it's permanently stopping use of the AstraZeneca vaccine. The New York Times. Updated April 14, 2021. Accessed August 6, 2021, https://www.nytimes.com/2021/04/14/world/europe/denmark-astrazeneca-vaccine.html 

  8. World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barre Syndrome (GBS) following adenovirus vector COVID-19 vaccines. Accessed August 6, 2021, https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs 

  9. Ang L, Lee HW, Choi JY, Zhang J, Lee MS. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integrative Medicine Research 2020;9(2):100407. 

    상세보기 crossref

  10. Korea Disease Control and Prevention Agency. Adverse Event Management Guidelines after Coronavirus Disease 19 Vaccination (1-3rd Edition). Accessed August 6, 2021 https://ncv.kdca.go.kr/board.es?mida12101000000&bid0031#content 

  11. Ministry of Food and Drug Safety. Guidelines for evaluating severity of adverse reactions in vaccine clinical trials. Accessed August 6, 2021, https://www.mfds.go.kr/brd/m_1060/view.do?seq13009&srchFr&srchTo&srchWord&srchTp&itm_seq_10&itm_seq_20&multi_itm_seq0&company_cd&company_nm&page83 

  12. US Food and Drug Administration. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Accessed August 6, 2021, https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical 

  13. World Health Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Accessed August 6, 2021, https://www.who.int/publications/m/item/WHO-causality-assessment 

  14. European Medicines Agency. Assessment report COVID-19 vaccine AstraZeneca. Accessed August 6, 2021, https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf 

  15. World Health Organization. Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca. Accessed August 6, 2021, https://www.who.int/publications/i/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca 

  16. Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. Journal of Korean Medical Science 2021;36(17):e115. 

    상세보기 crossref

  17. Nam Dj, Oh MS. Review about the Study of Ssanghwa-tang Published in Korea from 2000 to 2019. Journal of Haehwa Medicine 2019; 28(2):12-9. 

  18. Andrade RJ, Aithal GP, Bjorns on ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology 2019;70(6):1222-61. 

    상세보기 crossref

  19. Wang D, Liu Y, Zhao W. The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine. Frontiers in Molecular Biosciences 2021;8:655570. 

    상세보기 crossref

  20. Huang J, Tao G, Liu J, Cai J, Huang Z, Chen JX. Current Prevention of COVID-19: Natural Products and Herbal Medicine. Front Pharmacol 2020;11:588508. 

    상세보기 crossref

  21. Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K, et al. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine 2012;30(36):5368-72. 

    상세보기 crossref

  22. European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Public assessment report. Updated February 18, 2021. Accessed August 6, 2021, https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf 

저자의 다른 논문 :

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로